Literature DB >> 26923720

Outcome of ketogenic diets in GLUT1 deficiency syndrome in Japan: A nationwide survey.

Tatsuya Fujii1, Yasushi Ito2, Satoru Takahashi3, Kuriko Shimono4, Jun Natsume5, Keiko Yanagihara6, Hirokazu Oguni2.   

Abstract

OBJECTIVES: To evaluate the outcome of ketogenic diets (KDs) in patients with glucose transport type 1 deficiency syndrome (GLUT1DS) in Japan.
METHODS: A nationwide survey for GLUT1DS was conducted by sending questionnaires to board-certified pediatric neurologists nationwide to obtain clinical and laboratory data.
RESULTS: Among 39 patients whose diagnosis was confirmed molecularly or by the 3-O-methylglucose uptake assay, 31 were treated with KDs for longer than 1month. Seventeen patients (55%) were on the modified Atkins diet, 11 (35%) were on the classic KD, and 3 were on the medium-chain triglyceride (MCT) diet. The median values and ranges of serum β-hydroxybutyrate levels in patients on the modified Atkins diet, classic KD and MCT diet were 2.5mM (0.75-4.1), 1.7mM (0.23-3.5) and 2.6mM (1.5-3.0), respectively. The KDs were effective on seizures (80%), aggravation after fasting (80%) and ataxia (79%). Thus, ataxia was as responsive as seizures. Two patients on the classic KD with a ketogenic ratio as low as 1:1 showed improvement in neurological symptoms. The development or intelligence quotient measured using the same psychological scales before and after the KDs in 9 patients did not show a significant improvement; the median quotients before and after the diets were 40 (12-91) and 46 (12-67).
CONCLUSION: The KDs were most effective on seizures, transient aggravation after fasting and ataxia. The efficacy on intellectual development was equivocal. The modified Atkins diet was more commonly used for GLUT1DS in this study, and its ketogenicity was equivalent to the classic KD.
Copyright © 2016 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  DQ; Efficacy; GLUT1; Glucose transporter type 1 deficiency; IQ; Ketogenic diet; Modified Atkins diet

Mesh:

Substances:

Year:  2016        PMID: 26923720     DOI: 10.1016/j.braindev.2016.01.002

Source DB:  PubMed          Journal:  Brain Dev        ISSN: 0387-7604            Impact factor:   1.961


  6 in total

1.  Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome.

Authors:  Sachie Nakamura; Hitoshi Osaka; Shin-Ichi Muramatsu; Naomi Takino; Mika Ito; Shiho Aoki; Eriko F Jimbo; Kuniko Shimazaki; Tatsushi Onaka; Sumio Ohtsuki; Tetsuya Terasaki; Takanori Yamagata
Journal:  Mol Genet Metab Rep       Date:  2017-01-15

2.  Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer.

Authors:  Keisuke Hagihara; Katsufumi Kajimoto; Satoshi Osaga; Naoko Nagai; Eku Shimosegawa; Hideyuki Nakata; Hitomi Saito; Mai Nakano; Mariko Takeuchi; Hideaki Kanki; Kuriko Kagitani-Shimono; Takashi Kijima
Journal:  Nutrients       Date:  2020-05-19       Impact factor: 5.717

3.  Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet.

Authors:  Martin Voss; Nadja I Lorenz; Anna-Luisa Luger; Joachim P Steinbach; Johannes Rieger; Michael W Ronellenfitsch
Journal:  Int J Mol Sci       Date:  2018-08-20       Impact factor: 5.923

4.  Diagnostic Challenges Associated with GLUT1 Deficiency: Phenotypic Variabilities and Evolving Clinical Features.

Authors:  Hyuna Kim; Jin Sook Lee; Youngha Lee; Soo Yeon Kim; Byung Chan Lim; Ki Joong Kim; Murim Choi; Jong Hee Chae
Journal:  Yonsei Med J       Date:  2019-12       Impact factor: 2.759

Review 5.  A Review of Targeted Therapies for Monogenic Epilepsy Syndromes.

Authors:  Vincent Zimmern; Berge Minassian; Christian Korff
Journal:  Front Neurol       Date:  2022-02-17       Impact factor: 4.003

6.  Classic Ketogenic Diet and Modified Atkins Diet in SLC2A1 Positive and Negative Patients with Suspected GLUT1 Deficiency Syndrome: A Single Center Analysis of 18 Cases.

Authors:  Jana Ruiz Herrero; Elvira Cañedo Villarroya; Luis González Gutiérrez-Solana; Beatriz García Alcolea; Begoña Gómez Fernández; Laura Andrea Puerta Macfarland; Consuelo Pedrón-Giner
Journal:  Nutrients       Date:  2021-03-04       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.